No Differences

San Francisco - Alefacept (Amevive) offers efficacy for a broad spectrum of patients with chronic plaque psoriasis who are considered candidates for systemic therapy or phototherapy, according to the results of a retrospective study.

Related Videos
Related Content

New Guidelines to Prevent Food Allergies in Pediatric Atopic Dermatitis Patients

March 21st 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

25.1% of Patients Cited “Less Noticeable” Vitiligo in Recent Study

March 21st 2023

The Cutaneous Connection: JAK Inhibitor Safety for Treating AD

December 14th 2022

Indoor Tanning and Melanoma

March 21st 2023

Skin Barrier 101: Keep Up with What Your Patients Are Reading

March 21st 2023

New Guidelines to Prevent Food Allergies in Pediatric Atopic Dermatitis Patients

March 21st 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

25.1% of Patients Cited “Less Noticeable” Vitiligo in Recent Study

March 21st 2023

The Cutaneous Connection: JAK Inhibitor Safety for Treating AD

December 14th 2022

Indoor Tanning and Melanoma

March 21st 2023

Skin Barrier 101: Keep Up with What Your Patients Are Reading

March 21st 2023

New Guidelines to Prevent Food Allergies in Pediatric Atopic Dermatitis Patients

March 21st 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

25.1% of Patients Cited “Less Noticeable” Vitiligo in Recent Study

March 21st 2023

The Cutaneous Connection: JAK Inhibitor Safety for Treating AD

December 14th 2022

Indoor Tanning and Melanoma

March 21st 2023

Skin Barrier 101: Keep Up with What Your Patients Are Reading

March 21st 2023
© 2023 MJH Life Sciences

All rights reserved.